Pulmonary hypertension (PH) is a progressive cardiovascular disorder of multiple etiologies that typically ends in death due to right heart failure (HF). Based on the World Health Organization (WHO) classification of PH, it is divided into 5 groups, of which PH due to left heart disease (PH-LHD) is the commonest. PH-LHD is described as a PH subtype with mean pulmonary artery pressure (mPAP) >25 mmHg and pulmonary artery wedge pressure (PAWP) >15 mmHg, 1 although the threshold values of PAWP are controversial. 2 HF caused by LHD is mainly manifested as reduced ejection fraction (HFrEF), with preserved ejection fraction (HFpEF) and leftsided heart valve disease (VHD). 3 The occurrence of PH in patients with LHD is a sign of disease progression. 4 Nevertheless, therapeutic agents directly targeting patients with PH-LHD are not available.Although there have been some studies supporting the treatment of PH-LHD with targeted drugs for PAH, none has been applied to clinical treatment of PH-LHD. [5][6][7][8][9][10][11][12][13][14][15][16] Effective treatments for LHD do not seem to improve PH-LHD, 17 because PH-LHD is divided hemodynamically into pure postcapillary PH and combined pre-and